ArticlePLoS neglected tropical diseases2026
Cardiotoxin from Naja atra Activates the NLRP3/Caspase-1/GSDMD Pyroptosis Pathway to Induce Skin Tissue Injury.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiotoxin (CTX) from Naja atra venom is a principal virulence factor responsible for progressive local tissue necrosis and systemic inflammation following snakebite. Despite its clinical importance, the molecular mechanisms underlying CTX-induced skin injury remain poorly defined.
methodsWe employed a two-arm strategy combining transcriptome-guided discovery with mechanistic functional validation. In the transcriptomic arm, C57BL/6 mice received intradermal CTX injection (120 μg/50 μL), and skin tissues were harvested at 6, 12, and 24 h post-injection for RNA-seq analysis. Differentially expressed genes (DEGs) were screened and subjected to KEGG/GO enrichment and ssGSEA-based cell death mode scoring. In the functional validation arm, a separate cohort of mice was assessed at 72 h post-injection, with gross necrosis area quantified, followed by H&E staining, immunohistochemistry (IHC), and Western blot. In vitro validation was performed in human HaCaT keratinocytes using CCK-8 cytotoxicity assay, optical microscopy, transmission electron microscopy (TEM), propidium iodide/DAPI (PI/DAPI) dual staining, ROS detection, ELISA for IL-1β, LDH release assay, and pharmacological inhibition with MCC950 (NLRP3 inhibitor), VX-765 (caspase-1 inhibitor), and N-acetylcysteine (NAC, ROS scavenger).
resultsRNA-seq identified 2,490 DEGs (|log2FC| > 1, FDR < 0.01; 1,047 upregulated, 1,443 downregulated). KEGG enrichment revealed that the NOD-like receptor signaling pathway was the most significantly enriched pathway (enrichment fold = 6.8, p_adj < 0.001, with 42 differentially expressed genes annotated to this pathway). Among eight assessed cell death modalities, ssGSEA demonstrated that pyroptosis had the highest activation score (p < 0.05). Six canonical NLRP3/caspase-1/GSDMD pathway genes-Nlrp3, Pycard, Gsdmd, Il18, Nfkb, and Tlr4-were continuously upregulated from 6 to 24 h. Western blot confirmed both full-length GSDMD and its cleaved N-terminal fragment (GSDMD-N), along with NLRP3 inflammasome activation, in CTX-treated skin tissues and HaCaT cells. In vitro, CTX induced characteristic pyroptotic morphology and pyroptotic bodies (1-5 μm by TEM). Western blot confirmed NLRP3/GSDMD-N upregulation in HaCaT cells. CTX also induced dose-dependent intracellular ROS accumulation (DCFH-DA fluorescence). Importantly, all three inhibitors-NAC (ROS scavenger), MCC950 (NLRP3 inhibitor), and VX-765 (caspase-1 inhibitor)-significantly attenuated CTX-induced LDH release, IL-1β secretion, and GSDMD cleavage (all p < 0.0001), confirming the mechanistic hierarchy: ROS → NLRP3 → caspase-1 → GSDMD.
conclusionCTX induces intracellular ROS accumulation that activates the NLRP3/caspase-1/GSDMD pyroptotic cascade as an important mechanism contributing to skin tissue necrosis through membrane pore formation and inflammatory amplification. Pharmacological inhibition (NAC, MCC950, VX-765) confirmed a hierarchical ROS → NLRP3 → caspase-1 → GSDMD cascade. The ROS-NLRP3-caspase-1-GSDMD axis constitutes a tractable therapeutic target for Naja atra envenomation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.